389 related articles for article (PubMed ID: 12376557)
1. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.
Nagy P; Vereb G; Sebestyén Z; Horváth G; Lockett SJ; Damjanovich S; Park JW; Jovin TM; Szöllosi J
J Cell Sci; 2002 Nov; 115(Pt 22):4251-62. PubMed ID: 12376557
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
Lu Y; Zi X; Zhao Y; Pollak M
Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
4. Mapping ErbB receptors on breast cancer cell membranes during signal transduction.
Yang S; Raymond-Stintz MA; Ying W; Zhang J; Lidke DS; Steinberg SL; Williams L; Oliver JM; Wilson BS
J Cell Sci; 2007 Aug; 120(Pt 16):2763-73. PubMed ID: 17652160
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
7. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
8. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells.
Fiddes RJ; Janes PW; Sanderson GM; Sivertsen SP; Sutherland RL; Daly RJ
Cell Growth Differ; 1995 Dec; 6(12):1567-77. PubMed ID: 9019162
[TBL] [Abstract][Full Text] [Related]
9. Constitutively tyrosine phosphorylated p52 Shc in breast cancer cells: correlation with ErbB2 and p66 Shc expression.
Stevenson LE; Frackelton AR
Breast Cancer Res Treat; 1998 May; 49(2):119-28. PubMed ID: 9696394
[TBL] [Abstract][Full Text] [Related]
10. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells.
Qiu Y; Ravi L; Kung HJ
Nature; 1998 May; 393(6680):83-5. PubMed ID: 9590694
[TBL] [Abstract][Full Text] [Related]
11. Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells.
Sottocornola E; Misasi R; Mattei V; Ciarlo L; Gradini R; Garofalo T; Berra B; Colombo I; Sorice M
FEBS J; 2006 Apr; 273(8):1821-30. PubMed ID: 16623716
[TBL] [Abstract][Full Text] [Related]
12. Ligand-dependent recruitment of the ErbB4 signaling complex into neuronal lipid rafts.
Ma L; Huang YZ; Pitcher GM; Valtschanoff JG; Ma YH; Feng LY; Lu B; Xiong WC; Salter MW; Weinberg RJ; Mei L
J Neurosci; 2003 Apr; 23(8):3164-75. PubMed ID: 12716924
[TBL] [Abstract][Full Text] [Related]
13. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
Vijapurkar U; Kim MS; Koland JG
Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161
[TBL] [Abstract][Full Text] [Related]
14. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
Sak MM; Szymanska M; Bertelsen V; Hasmann M; Madshus IH; Stang E
Carcinogenesis; 2013 Sep; 34(9):2031-8. PubMed ID: 23698633
[TBL] [Abstract][Full Text] [Related]
15. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
Holbro T; Beerli RR; Maurer F; Koziczak M; Barbas CF; Hynes NE
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8933-8. PubMed ID: 12853564
[TBL] [Abstract][Full Text] [Related]
16. ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment.
Váradi T; Roszik J; Lisboa D; Vereb G; Molina-Guijarro JM; Galmarini CM; Szöllosi J; Nagy P
Eur J Pharmacol; 2011 Sep; 667(1-3):91-9. PubMed ID: 21658382
[TBL] [Abstract][Full Text] [Related]
17. Homo- and Heteroassociations Drive Activation of ErbB3.
Váradi T; Schneider M; Sevcsik E; Kiesenhofer D; Baumgart F; Batta G; Kovács T; Platzer R; Huppa JB; Szöllősi J; Schütz GJ; Brameshuber M; Nagy P
Biophys J; 2019 Nov; 117(10):1935-1947. PubMed ID: 31653451
[TBL] [Abstract][Full Text] [Related]
18. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
Muthuswamy SK; Gilman M; Brugge JS
Mol Cell Biol; 1999 Oct; 19(10):6845-57. PubMed ID: 10490623
[TBL] [Abstract][Full Text] [Related]
19. The Dipole Potential Modifies the Clustering and Ligand Binding Affinity of ErbB Proteins and Their Signaling Efficiency.
Kovács T; Batta G; Hajdu T; Szabó Á; Váradi T; Zákány F; Csomós I; Szöllősi J; Nagy P
Sci Rep; 2016 Oct; 6():35850. PubMed ID: 27775011
[TBL] [Abstract][Full Text] [Related]
20. Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
Mocanu MM; Fazekas Z; Petrás M; Nagy P; Sebestyén Z; Isola J; Tímár J; Park JW; Vereb G; Szöllosi J
Cancer Lett; 2005 Sep; 227(2):201-12. PubMed ID: 16112423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
